NantHealth, Inc. (NH)
(Delayed Data from NSDQ)
$0.68 USD
-0.01 (-0.74%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.67 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.68 USD
-0.01 (-0.74%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.67 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
NantHealth, Inc. (NH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
NantHealth, Inc. (NH) delivered earnings and revenue surprises of -11.11% and 0.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: NantHealth, Inc. (NH) Q4 Earnings Expected to Decline
by Zacks Equity Research
NantHealth, Inc. (NH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Outset Medical, Inc. (OM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Outset Medical, Inc. (OM) delivered earnings and revenue surprises of -14.93% and 6.04%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
NantHealth, Inc. (NH) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
NantHealth, Inc. (NH) delivered earnings and revenue surprises of -25.00% and -18.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: NantHealth, Inc. (NH) Q3 Earnings Expected to Decline
by Zacks Equity Research
NantHealth, Inc. (NH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NantHealth, Inc. (NH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
NantHealth, Inc. (NH) delivered earnings and revenue surprises of 20.00% and -5.35%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate NantHealth, Inc. (NH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
NantHealth, Inc. (NH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights: Omnicell, NextGen Healthcare, NantHealth, Allscripts Healthcare Solutions and Quest Diagnostics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Omnicell, NextGen Healthcare, NantHealth, Allscripts Healthcare Solutions and Quest Diagnostics
3 Top Medical Info Systems Stocks to Beat COVID-19 Resurgence Crisis
by Urmimala Biswas
Despite the severe challenges posed by the COVID-19 pandemic, higher demand for telemedicine, digital influence and AI is likely to lend support to the Zacks Medical - Information industry. OMCL, NXGN and NH are well positioned to gain.
Implied Volatility Surging for NantHealth (NH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to NantHealth (NH) stock based on the movements in the options market lately.
NantHealth, Inc. (NH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
NantHealth, Inc. (NH) delivered earnings and revenue surprises of -16.67% and -3.38%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
NantHealth (NH) Looks Good: Stock Adds 9.1% in Session
by Zacks Equity Research
NantHealth (NH) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
NantHealth Inc (NH) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
NantHealth Inc (NH) delivered earnings and revenue surprises of 14.29% and -5.80%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
NantHealth, Inc. (NH) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
NantHealth, Inc. (NH) delivered earnings and revenue surprises of -75.00% and -4.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
NantHealth, Inc. (NH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
NantHealth, Inc. (NH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NantHealth, Inc. (NH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
NantHealth, Inc. (NH) delivered earnings and revenue surprises of 55.56% and 7.03%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
NantHealth, Inc. (NH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
NantHealth, Inc. (NH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Invitae (NVTA) Catches Eye: Stock Jumps 9.1%
by Zacks Equity Research
Invitae (NVTA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
NantHealth, Inc. (NH) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
NantHealth, Inc. (NH) delivered earnings and revenue surprises of 23.08% and -10.83%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will NantHealth, Inc. (NH) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
NantHealth, Inc. (NH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NantHealth, Inc. (NH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
NantHealth, Inc. (NH) delivered earnings and revenue surprises of -11.11% and -10.01%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
NantHealth (NH) Shares March Higher, Can It Continue?
by Zacks Equity Research
NantHealth Inc (NH) has been on the move lately as the stock has risen by 5.7% in the past four weeks, and it is currently trading well above its 20-Day SMA
What Makes NantHealth (NH) a Strong Sell?
by Zacks Equity Research
NantHealth (NH), has witnessed a significant price decline and negative trend in earnings estimate revisions